Biomedicine is the No. 1 industry leading the future development of Suzhou Industrial Park. In the 2020 China Biomedical Industrial Park Competitiveness Ranking released by the China Biotechnology Development Center, Suzhou Industrial Park ranks first among 215 industrial parks in the country in terms of comprehensive competitiveness, industrial competitiveness, talent competitiveness, and technological competitiveness. At present, the park has gathered 2018 biopharmaceutical enterprises of various types, with an industrial output value of 117.7 billion yuan.

The park gathers 85 listed companies and innovative leading companies in biopharmaceuticals, accounting for more than 20% of similar companies in the country. There are 126 national-level entrepreneurial top talents in biomedicine, accounting for more than 20% of that in the country. In 2021, the market financing of biopharmaceutical enterprises will be about 20 billion yuan, accounting for more than 20% of the national total in the same period. For three years in a row, the park has been home to 20% of China's innovative startups, top-notch professionals, and clinical approvals for Category 1 new drugs.

With unique geographical advantages, the College of Pharmaceutical Sciences has established close cooperation with the biotech/biopharma corporations in the Industrial Park, which provides excellent opportunities for thetranslation of academic resultsand multidisciplinary innovations.